Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Part of Hypertension

Subtypes of Pulmonary Arterial Hypertension

Connective tissue disease-associated pulmonary arterial hypertension 1 Sjögren’s syndrome-associated pulmonary arterial hypertension 1 Systemic lupus erythematosus-associated pulmonary arterial hypertension 1 Systemic sclerosis-associated pulmonary arterial hypertension 1

8 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Pulmonary Arterial Hypertension

102 trials tracked for Pulmonary Arterial Hypertension: 53 in phase 3 or 4 and 22 with published results. The most-cited published study has 713 citations.

102Trials tracked
53Phase 3 & 4
0Recruiting
22With published results
Phase distribution
Phase 4 19 Phase 3 34 Phase 2 33 Phase 1 5 Other / NA 11
  1. Phase 3 A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR) Completed · 713 cited
  2. Phase 4 A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis Completed · 173 cited
  3. Phase 3 The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension Completed · 171 cited
  4. Phase 4 Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy Completed · 162 cited
  5. Phase 3 Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy Completed · 155 cited
  6. Phase 3 A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) Completed · 150 cited
Show 44 more trials
  1. Phase 3 Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome Completed · 130 cited
  2. Phase 3 Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument Completed · 65 cited
  3. Phase 4 Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension Completed · 61 cited
  4. Phase 4 REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension Completed · 57 cited
  5. Phase 3 Bosentan in Children With Pulmonary Arterial Hypertension Extension Study Completed · 45 cited
  6. Phase 4 Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension. Completed · 38 cited
  7. Phase 3 ACT-293987 in Pulmonary Arterial Hypertension Completed · 34 cited
  8. Phase 3 Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension Completed · 33 cited
  9. Phase 3 Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension Completed · 18 cited
  10. Phase 3 A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007) Completed · 17 cited
  11. Phase 4 EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension Completed · 8 cited
  12. Phase 3 Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension Completed · 7 cited
  13. Phase 3 An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension Completed · 5 cited
  14. Phase 4 Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication Completed · 4 cited
  15. Phase 3 A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020) Completed · 2 cited
  16. Phase 3 A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) Completed
  17. Phase 4 BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology Completed
  18. Phase 4 Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension Completed
  19. Phase 4 TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH) Completed
  20. Phase 4 Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID) Completed
  21. Phase 4 Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension Completed
  22. Phase 4 Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects Completed
  23. Phase 4 Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401 Completed
  24. Phase 4 Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) Completed
  25. Phase 4 Combination Therapy in Pulmonary Arterial Hypertension Completed
  26. Phase 4 Epoprostenol for Injection in Pulmonary Arterial Hypertension Completed
  27. Phase 4 Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension Completed
  28. Phase 4 Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1) Completed
  29. Phase 3 A Pharmacokinetic Substudy of the TDE-PH-304 Protocol Completed
  30. Phase 3 Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension Completed
  31. Phase 3 Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension Completed
  32. Phase 3 FUTURE 3 Study Extension Completed
  33. Phase 3 Beraprost-314d Added-on to Tyvaso® (BEAT) Completed
  34. Phase 3 An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension Completed
  35. Phase 3 Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants Completed
  36. Phase 3 A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension Completed
  37. Phase 3 Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension Completed
  38. Phase 3 A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children Completed
  39. Phase 3 A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202) Completed
  40. Phase 3 Selexipag (ACT-293987) in Pulmonary Arterial Hypertension Completed
  41. Phase 3 Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension Completed
  42. Phase 3 Ranolazine and Pulmonary Hypertension Completed
  43. Phase 3 Iloprost Power 15 in Pulmonary Arterial Hypertension Completed
  44. Phase 3 Imatinib (QTI571) in Pulmonary Arterial Hypertension Completed

Showing the 50 most-cited and recently-updated of 102 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Pulmonary Arterial Hypertension: what the trials found

Several therapies have demonstrated significant improvements in clinical markers for pulmonary arterial hypertension. Sotatercept showed a statistically significant increase in 6-minute walk distance (6MWD) and a significant reduction in pulmonary vascular resistance (PVR) at week 24 20. Treprostinil diolamine was associated with a significant reduction in NT-proBNP levels by week 24 22, while inhaled treprostinil significantly improved 6MWD and CAMPHOR quality of life scores 16.

Other interventions showed varying degrees of efficacy. Riociguat demonstrated a statistically significant improvement in the number of participants with satisfactory clinical response at week 24 2. Macitentan was evaluated for PVR, 6MWD, and NT-proBNP levels, though results did not reach statistical significance compared to the control 21. Bosentan trials showed mixed results; while one study reported a significant change in 6MWD 12, another trial showed no significant difference in 6MWD at week 12 14.

Additional findings include a reduction in Borg Dyspnea Scores with treprostinil 6 and remodulin 8, as well as improvements in pulmonary vascular resistance with macitentan 4. Sildenafil was associated with changes in WHO functional class, blood pressure, and heart rate over an extended period 10.

Ambrisentan was associated with a recorded mean change in 6MWD at 12 weeks 13 and various improvements in 6MWD, Dyspnea Index, and CAMPHOR scores across multiple time points 19.

For the clinician treating this condition

  • Sotatercept is associated with significant improvements in both functional capacity (6MWD) and hemodynamic markers (PVR) at 24 weeks.
  • Treprostinil (both diolamine and inhaled forms) shows consistent evidence for improving patient outcomes, including NT-proBNP levels and quality of life scores.
  • Clinical responses to Riociguart and Bosentan vary; while Riociguart showed significant clinical response at 24 weeks, Bosentan's impact on 6MWD was not consistently significant across different study designs.

AI synthesis of 13 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Multidisciplinary management strategies improve outcomes for pregnant women with pulmonary arterial hypertension
Diabetes & Endocrinology Sys. Review
Multidisciplinary management strategies improve outcomes for pregnant women with pulmonary arterial hypertension New management strategies for pregnant women with pulmonary arterial hypertension
This narrative review synthesizes management strategies for the preconception, antenatal, and postpartum periods in patients with pulmonary …
Managing high blood pressure in the lungs during pregnancy requires a team approach to keep both mother and baby safe before, during, and af…
Frontiers Aug 10, 2026
Vascular smooth muscle cell immune interactions drive remodeling across cardiovascular diseases
Oncology Sys. Review
Vascular smooth muscle cell immune interactions drive remodeling across cardiovascular diseases How blood vessel cells drive heart disease and high blood pressure
This narrative review synthesizes mechanisms of VSMC-immune interactions in atherosclerosis, hypertension, aortic aneurysms, and arteritis. …
A new review reveals how blood vessel cells change in heart disease, high blood pressure, and more.
Frontiers Jun 7, 2026
Mechanical shear stress influences endothelial RNA methylation in atherosclerosis and pulmonary arterial hypertension
Genetics & Precision Medicine Sys. Review
Mechanical shear stress influences endothelial RNA methylation in atherosclerosis and pulmonary arterial hypertension Mechanical forces on blood vessel cells may change how they repair themselves
This narrative review examines the interplay between hemodynamic shear stress and epitranscriptomic mechanisms in endothelial cells. The aut…
New review suggests blood flow forces might alter how RNA works in cells lining our vessels, potentially affecting heart and lung health.
Frontiers Jun 5, 2026
Narrative review highlights limited data on connective tissue disease-associated PAH in Han Chinese populations
Rheumatology Sys. Review
Narrative review highlights limited data on connective tissue disease-associated PAH in Han Chinese populations New data reveals how lung pressure risks differ for Chinese patients with connective tissue disease
This narrative review examines connective tissue disease-associated pulmonary arterial hypertension, specifically systemic sclerosis-associa…
A new review shows that lung pressure risks for Chinese patients with connective tissue disease differ from Western populations and require …
Frontiers May 6, 2026
Systematic review of immunosuppression for SLE-associated intestinal pseudo-obstruction
Allergy & Immunology Meta-analysis
Systematic review of immunosuppression for SLE-associated intestinal pseudo-obstruction SLE Can Shut Down the Gut — But It Might Be Reversible
This review synthesized 43 cases of SLE-associated intestinal pseudo-obstruction.
Lupus can paralyze the gut without a blockage, but early treatment with immunosuppressives often reverses this dangerous complication.
Frontiers Apr 20, 2026
Inflammatory and metabolic markers differ across systemic sclerosis lung phenotypes in retrospective study
Rheumatology Cohort
Inflammatory and metabolic markers differ across systemic sclerosis lung phenotypes in retrospective study Scleroderma Lung Damage May Leave Hidden Clues in Blood
A retrospective cross-sectional study of 314 SSc inpatients found higher inflammatory markers (ESR, hs-CRP, CRP/albumin ratio, SII) and anti…
Routine blood tests may soon reveal hidden lung damage patterns in scleroderma patients, helping doctors spot dangerous complications before…
Frontiers Apr 16, 2026
FDA Approves Winrevair for Pulmonary Arterial Hypertension (PAH) in Adults
Pulmonology & Critical Care FDA Approval
FDA Approves Winrevair for Pulmonary Arterial Hypertension (PAH) in Adults FDA approves a new treatment for a serious lung condition called pulmonary arterial hypertension
The FDA has approved Winrevair for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to improve exercise capac…
A new FDA-approved injection helps adults with pulmonary arterial hypertension exercise longer, improve daily life, and lower the risk of ho…
FDA Mar 31, 2026
Parenteral Treprostinil Shows Efficacy in Pediatric PAH, Meta-Analysis Confirms
Pediatrics Meta-analysis
Parenteral Treprostinil Shows Efficacy in Pediatric PAH, Meta-Analysis Confirms Can parenteral treprostinil help kids with pulmonary arterial hypertension?
Meta-analysis of 143 patients shows parenteral treprostinil benefits in pediatric PAH. Data supports efficacy and safety.
Parenteral treprostinil shows clear treatment benefits and safety for children with pulmonary arterial hypertension, offering hope for famil…
Mar 28, 2026

Research across Hypertension

Related studies from across the Hypertension family.

Plasticisers disrupt the hypothalamic-pituitary-thyroid axis and potentially contribute to cardiovascular dysfunction
Drug Pipeline Sys. Review
Plasticisers disrupt the hypothalamic-pituitary-thyroid axis and potentially contribute to cardiovascular dysfunction Plasticisers May Link Thyroid Issues to Heart Health Problems
This narrative review explores how plasticisers, including phthalates and bisphenols, interfere with thyroid hormone synthesis, transport, a…
Common chemicals called plasticisers may disrupt thyroid hormones, which could lead to heart issues like high blood pressure and heart failu…
Frontiers Sep 14, 2026
NewSTeP protocol using single-pill combinations for hypertension is currently being evaluated in a trial
Cardiology RCT
NewSTeP protocol using single-pill combinations for hypertension is currently being evaluated in a trial New trial tests single-pill combinations for high blood pressure
This randomized clinical trial protocol describes the NewSTeP intervention for adults with hypertension in India. The study aims to evaluate…
A new clinical trial in India is testing if combining multiple blood pressure medications into one pill improves treatment for patients.
medRxiv Sep 12, 2026
Metabolic syndrome affects 21.3% of Nepalese adults but extreme heterogeneity limits national estimates
Cardiology Meta-analysis
Metabolic syndrome affects 21.3% of Nepalese adults but extreme heterogeneity limits national estimates New data reveals high rates of metabolic syndrome in Nepal
This meta-analysis estimates metabolic syndrome prevalence among Nepalese adults at 21.3%, with low HDL (64.5%) and abdominal obesity (59.5%…
Over 20 percent of adults in Nepal show signs of metabolic syndrome, a cluster of conditions like high blood pressure and obesity.
medRxiv Sep 12, 2026
Structured Tai Chi programs significantly reduce blood pressure and atherogenic lipid markers in older women
Cardiology Meta-analysis
Structured Tai Chi programs significantly reduce blood pressure and atherogenic lipid markers in older women Tai Chi May Lower Blood Pressure in Older Women
This systematic review and meta-analysis evaluates structured Tai Chi programs for managing cardiometabolic risk factors in middle-aged and …
Structured Tai Chi programs may help lower blood pressure and certain cholesterol levels in middle-aged and older women with hypertension.
Frontiers Sep 9, 2026
Tai Chi provides positive effects for balance, mood, and cognitive performance in older adults
Primary Care & Family Medicine Guideline
Tai Chi provides positive effects for balance, mood, and cognitive performance in older adults Tai Chi Shows Positive Effects for Older Adults with Parkinson's
This evidence map synthesized 118 systematic reviews regarding Tai Chi for older adults. The findings indicate positive effects for balance,…
Tai Chi may help older adults improve balance, reduce anxiety, and manage symptoms of Parkinson's disease and other age-related conditions.
Frontiers Sep 8, 2026
Syndrome-informed Traditional Chinese Medicine improves sleep quality and reduces blood pressure in patients with comorbid hypertension and insomnia
Diabetes & Endocrinology Meta-analysis
Syndrome-informed Traditional Chinese Medicine improves sleep quality and reduces blood pressure in patients with comorbid hypertension and insomnia Traditional Chinese Medicine may improve sleep and blood pressure
This meta-analysis of 12 trials indicates that syndrome-informed Traditional Chinese Medicine significantly improves sleep quality (SMD -2.2…
New data suggests that syndrome-informed Traditional Chinese Medicine can improve sleep quality and lower blood pressure for adults with bot…
Frontiers Sep 4, 2026
Preservative Free Bimatoprost 0.01% Shows Non Inferiority to Higher Concentration Formulations
Ophthalmology Sys. Review
Preservative Free Bimatoprost 0.01% Shows Non Inferiority to Higher Concentration Formulations Preservative-free bimatoprost shows similar results for glaucoma eye pressure
Preservative-free bimatoprost 0.01% provides comparable intraocular pressure reduction to higher concentrations with improved local tolerabi…
A new look at eye drops shows that preservative-free bimatoprost lowers eye pressure as well as stronger versions with fewer side effects.
Sep 4, 2026
Wuqinxi exercise reduces systolic and diastolic blood pressure in adults with primary hypertension
Rheumatology Meta-analysis
Wuqinxi exercise reduces systolic and diastolic blood pressure in adults with primary hypertension Wuqinxi Exercise Lowers Blood Pressure in Hypertensive Adults
This meta-analysis of 770 participants indicates that Wuqinxi exercise reduces systolic blood pressure by 5.3 mmHg and diastolic blood press…
A meta-analysis finds Wuqinxi, a traditional Chinese exercise, may lower blood pressure in middle-aged and older adults with hypertension.
Frontiers Sep 3, 2026
Metabolic risk factors including diabetes and metabolic syndrome are associated with increased hepatocellular carcinoma risk
Rheumatology Meta-analysis
Metabolic risk factors including diabetes and metabolic syndrome are associated with increased hepatocellular carcinoma risk Metabolic risk factors linked to higher liver cancer risk
This meta-analysis of cohort studies involving more than 45 million participants identifies significant associations between metabolic risk …
New data from over 45 million people show that conditions like diabetes and high blood pressure are linked to a higher risk of liver cancer.
Frontiers Aug 29, 2026
Fatty pancreas prevalence 30.5% and linked to higher pancreatitis, cancer risk
Psychiatry Meta-analysis
Fatty pancreas prevalence 30.5% and linked to higher pancreatitis, cancer risk Fatty pancreas is linked to higher risk of pancreatic cancer
This meta-analysis of 124 studies including 141,416 healthy or routine-examination participants found a fatty pancreas prevalence of 30.5%, …
A fatty pancreas is common and linked to a higher risk of serious conditions like pancreatic cancer and diabetes.
Frontiers Aug 28, 2026
Habitual tea consumption is associated with 13% lower hypertension risk in cohort studies
Nutrition & Obesity Medicine Meta-analysis
Habitual tea consumption is associated with 13% lower hypertension risk in cohort studies Regular tea drinking may lower risk of high blood pressure
This meta-analysis of 319,565 adults found that habitual tea consumption is weakly associated with lower hypertension prevalence (OR = 0.92)…
A large study involving over 300,000 adults suggests that habitual tea consumption is linked to a lower risk of hypertension.
Frontiers Aug 24, 2026
Combined training reduces 24-hour systolic blood pressure by 6.18 mm Hg in adults with hypertension
Physical Medicine & Rehab Sys. Review
Combined training reduces 24-hour systolic blood pressure by 6.18 mm Hg in adults with hypertension Different types of exercise show promise for managing high blood pressure
This network meta-analysis of 31 trials involving 1345 participants with hypertension found that combined, aerobic, and high-intensity inter…
Various forms of exercise, including aerobic and interval training, are linked to lower 24-hour blood pressure readings for adults with hype…
Aug 23, 2026

Questions about Pulmonary Arterial Hypertension

Does the new drug Winrevair improve exercise capacity for people with Pulmonary Arterial Hypertension?

Yes, the drug Winrevair (sotatercept) improves exercise capacity in adults with pulmonary arterial hypertension by increasing distance walked and oxygen use.

Full answer →
Can parenteral treprostinil help children with pediatric Pulmonary Arterial Hypertension based on recent studies?

Yes, recent studies show parenteral treprostinil can improve outcomes in children with PAH, though evidence is from observational studies, not large trials.

Full answer →